Form 8-K - Current report:
SEC Accession No. 0001213900-26-037497
Filing Date
2026-03-31
Accepted
2026-03-31 16:29:26
Documents
12
Period of Report
2026-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0284372-8k_endralife.htm   iXBRL 8-K 33311
2 PRESS RELEASE DATED MARCH 31, 2026, FURNISHED HEREWITH ea028437201ex99-1.htm EX-99.1 57916
  Complete submission text file 0001213900-26-037497.txt   265913

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ndra-20260331.xsd EX-101.SCH 3014
4 XBRL LABEL FILE ndra-20260331_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE ndra-20260331_pre.xml EX-101.PRE 22358
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0284372-8k_endralife_htm.xml XML 3212
Mailing Address 3600 GREEN COURT SUITE 350 ANN ARBOR MI 48105
Business Address 3600 GREEN COURT SUITE 350 ANN ARBOR MI 48105 734-335-0468
ENDRA Life Sciences Inc. (Filer) CIK: 0001681682 (see all company filings)

EIN.: 260579295 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37969 | Film No.: 26822419
SIC: 3845 Electromedical & Electrotherapeutic Apparatus
(CF Office: 08 Industrial Applications and Services)